Awakn Life Sciences Corp.
AWKNF · OTC
10/31/2024 | 7/31/2024 | 4/30/2024 | 1/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -66.6% | -46.8% | -5.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 77% | 78.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $0 | $0 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -12,856.5% | -5,297.3% | -2,535% | -3,861% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$1 | -$1 |
| % Margin | -10,248.7% | -3,283.5% | -2,634.6% | -4,698.4% |
| EPS | -0.011 | -0.011 | -0.014 | -0.026 |
| % Growth | -4.7% | 23.7% | 46.9% | – |
| EPS Diluted | -0.011 | -0.011 | -0.014 | -0.026 |
| Weighted Avg Shares Out | 34 | 34 | 39 | 39 |
| Weighted Avg Shares Out Dil | 34 | 34 | 39 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | -12,735.4% | -5,255% | -2,511.9% | -3,839.2% |